Analysts Expect Clementia Pharmaceuticals Inc (CMTA) to Post -$0.34 EPS

Brokerages expect Clementia Pharmaceuticals Inc (NASDAQ:CMTA) to post ($0.34) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Clementia Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.43) and the highest is ($0.27). The company is expected to announce its next earnings results on Monday, February 12th.

On average, analysts expect that Clementia Pharmaceuticals will report full-year earnings of ($7.83) per share for the current financial year, with EPS estimates ranging from ($8.12) to ($7.53). For the next year, analysts forecast that the company will report earnings of ($1.35) per share, with EPS estimates ranging from ($1.57) to ($1.11). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Clementia Pharmaceuticals.

Clementia Pharmaceuticals (NASDAQ:CMTA) last released its quarterly earnings data on Monday, November 13th. The company reported ($1.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($1.52).

CMTA has been the subject of several research analyst reports. Wedbush restated an “outperform” rating and issued a $26.00 price objective on shares of Clementia Pharmaceuticals in a research note on Tuesday, November 14th. Zacks Investment Research downgraded shares of Clementia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, January 15th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $27.00.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Alps Advisors Inc. acquired a new stake in shares of Clementia Pharmaceuticals during the fourth quarter worth about $642,000. Victory Capital Management Inc. boosted its stake in shares of Clementia Pharmaceuticals by 12.7% during the fourth quarter. Victory Capital Management Inc. now owns 34,710 shares of the company’s stock worth $659,000 after buying an additional 3,920 shares during the period. Susquehanna International Group LLP acquired a new stake in shares of Clementia Pharmaceuticals during the third quarter worth about $729,000. Neuberger Berman Group LLC acquired a new stake in shares of Clementia Pharmaceuticals during the third quarter worth about $1,689,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Clementia Pharmaceuticals during the third quarter worth about $506,000. Institutional investors and hedge funds own 68.40% of the company’s stock.

Clementia Pharmaceuticals (CMTA) opened at $13.22 on Friday. Clementia Pharmaceuticals has a 12 month low of $12.86 and a 12 month high of $20.15.

TRADEMARK VIOLATION WARNING: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/13/analysts-expect-clementia-pharmaceuticals-inc-cmta-to-post-0-34-eps.html.

About Clementia Pharmaceuticals

Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.

Get a free copy of the Zacks research report on Clementia Pharmaceuticals (CMTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply